Recommendations for approval

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2011年 / 46卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：400 / 401
页数：2
相关论文
共 50 条
  • [21] Effects of an extended MRI approval of an implantable spinal cord stimulation device on compliance with manufacturer's recommendations
    Reining, Marco
    Winkler, Dirk
    Kirchhof, Klaus
    Boettcher, Joachim
    Kretzschmar, Michael
    PAIN PRACTICE, 2025, 25 (04)
  • [22] Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
    Kakkis, Emil D.
    O'Donovan, Mary
    Cox, Gerald
    Hayes, Mark
    Goodsaid, Federico
    Tandon, P. K.
    Furlong, Pat
    Boynton, Susan
    Bozic, Mladen
    Orfali, May
    Thornton, Mark
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [23] Practical aspects and recommendations concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America
    Steinberg, Judith
    Fragoso, Yara
    Garcia Bonitto, Juan Raul
    Guerra, Carolina
    Rodriguez, Virginia
    Correa, Patricio
    Macias, Miguel
    Novarro, Nelson
    Vizcarra, Darwin
    Orozco, Geraldine
    Carra, Adriana
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 136 - 137
  • [24] Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
    Emil D Kakkis
    Mary O’Donovan
    Gerald Cox
    Mark Hayes
    Federico Goodsaid
    PK Tandon
    Pat Furlong
    Susan Boynton
    Mladen Bozic
    May Orfali
    Mark Thornton
    Orphanet Journal of Rare Diseases, 10
  • [25] Institutional Review Board-Based Recommendations for Medical Institutions Pursuing Protocol Approval for Facial Transplantation
    Siemionow, Maria Z.
    Gordon, Chad R.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2010, 126 (04) : 1232 - 1239
  • [26] Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs
    Similon, Miriam von Mucke
    Paasche, Cecilia
    Krol, Fas
    Lerer, Bernard
    Goodwin, Guy M.
    Berk, Michael
    Meyer-Lindenberg, Andreas
    Ketter, Terence A.
    Yatham, Lakshmi N.
    Goldberg, Joseph F.
    Malhi, Gin S.
    El-Mallakh, Rif
    Licht, Rasmus W.
    Young, Allan H.
    Kapczinski, Flavio
    Swartz, Marnina
    Hagin, Michal
    Torrent, Carla
    Serretti, Alessandro
    Yildiz, Aysegul
    Martinez-Aran, Anabel
    Strejilevich, Sergio
    Rybakowski, Janusz
    Sani, Gabriele
    Grunze, Heinz
    Vazquez, Gustavo
    Pinto, Ana Gonzales
    Azorin, Jean Michel
    Nolen, Willem
    Sentissi, Othman
    Lopez-Jaramillo, Carlos
    Frey, Benicio N.
    Nierenberg, Andrew
    Parker, Gordon
    Bond, David J.
    Cohen, Adam
    Tortorella, Alfonso
    Perugi, Giulio
    Vieta, Eduard
    Popovic, Dina
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2022, 60 : 91 - 99
  • [27] Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
    McPhail, Melanie
    Weiss, Emma
    Bubela, Tania
    FRONTIERS IN MEDICINE, 2022, 8
  • [28] Early Approval Versus Late Approval
    Pignatti, F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S38 - S38
  • [29] Accelerated Approval Is Not Conditional Approval Insights From International Expedited Approval Programs
    Mehta, Gautam U.
    de Claro, R. Angelo
    Pazdur, Richard
    JAMA ONCOLOGY, 2022, 8 (03) : 335 - 336
  • [30] 'ON APPROVAL'
    HUGHES, D
    DRAMA, 1982, (146): : 40 - 41
12345